Program
Rabeprazole
Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.
Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.
Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 210 open or running | phase 3since Sep 12, 2005 | Aug 19, 2005 | none ahead |
| Johnson & Johnson | 150 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since May 14, 2015 | Sep 26, 2013 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lomond Therapeuticsits history only | 20 open or running | phase 1since May 1, 2024 | May 1, 2024 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since May 16, 2022 | May 16, 2022 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since May 20, 2013 | May 20, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jun 15, 2015 | Jun 15, 2015 | none ahead |
| Neutec Ar-Ge San ve Tic A.Şits history only | 10 open or running | phase 4since Feb 10, 2016 | Feb 10, 2016 | none ahead |
| PriCara, Unit of Ortho-McNeilits history only | 10 open or running | phase 4since Oct 7, 2005 | Oct 7, 2005 | none ahead |
| Yungjin Pharm.its history only | 10 open or running | phase 1since Jan 7, 2021 | Jan 7, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First studies: 2 phase 4 studiesFirst studyNCT00216489, NCT00216450
- Oct 7, 2005Phase 3 study in Gastroesophageal RefluxNCT00236392 · 422 enrolled
- Sep 15, 2006Phase 1 study in Gastroesophageal RefluxNCT00378287 · 37 enrolled
- Apr 20, 2007Phase 4 study in Gastroesophageal RefluxNCT00464308 · 1,392 enrolled · Australia
- Nov 1, 2007Phase 3 study in Gastroesophageal RefluxNCT00553449 · 48 enrolled
- Sep 4, 20082 phase 1 studies in Gastroesophageal RefluxNCT00747695, NCT00747526
- Nov 6, 2008Phase 3 study in Gastroesophageal RefluxNCT00787891 · 127 enrolled
- Mar 2, 2009Phase 1 study in Gastroesophageal RefluxNCT00855361 · 69 enrolled · United States, Germany, Poland and more
- Sep 4, 2009Phase 3 study in Gastroesophageal RefluxNCT00992589 · 344 enrolled · United States, Australia, Belgium and more
- Nov 5, 2009Phase 4 study in Esophagitis, PepticNCT01008696 · 217 enrolled
- Mar 11, 2010Phase 1 study in Gastroesophageal RefluxNCT01101646 · 36 enrolled · United States
- Aug 19, 2010Phase 1 study in HealthyNCT01186497 · 35 enrolled
- Oct 21, 2010Phase 1 study in HealthyNCT01241409 · 78 enrolled
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 15 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01241409Healthy | 1 | Completed | Dec 2010 | 78 |
| NCT01186497Healthy | 1 | Completed | Nov 2010 | 35 |
| NCT01101646Gastroesophageal Reflux · United States | 1 | Completed | Sep 2008 | 36 |
| NCT01008696Esophagitis, Peptic | 4 | Completed | Aug 2008 | 217 |
| NCT00992589Gastroesophageal Reflux · United States, Australia, Belgium and more | 3 | Completed | Nov 2011 | 344 |
| NCT00855361Gastroesophageal Reflux · United States, Germany, Poland and more | 1 | Completed | Dec 2011 | 69 |
| NCT00787891Gastroesophageal Reflux | 3 | Completed | Jan 2011 | 127 |
| NCT00747695Gastroesophageal Reflux | 1 | Completed | 31 | |
| NCT00747526Gastroesophageal Reflux · United States, Belgium, Brazil and more | 1 | Completed | Feb 2012 | 51 |
| NCT00553449Gastroesophageal Reflux | 3 | Completed | 48 | |
| NCT00464308Gastroesophageal Reflux · Australia | 4 | Completed | May 2008 | 1,392 |
| NCT00378287Gastroesophageal Reflux | 1 | Completed | 37 | |
| NCT00236392Gastroesophageal Reflux | 3 | Completed | 422 | |
| NCT00216489Gastroesophageal Reflux | 4 | Completed | 191 | |
| NCT00216450Helicobacter Infections | 4 | Completed | 80 |
How it is read
Names in the registry
- “Rabeprazole”, 15 entries
- “rabeprazole”, 14 entries
- “rabeprazole sodium”, 10 entries
- “E3810”, 8 entries
- “Rabeprazole sodium”, 6 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 25 studies
- Esophagitis, Peptic, 3 studies
- Gastrointestinal Diseases, 2 studies
- Stomach Ulcer, 2 studies
- Heartburn, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.